Alebachew Kindie
Psychiatric/Mental Health · San Antonio, TXNPI 1538601075
Payments from drug & device makers
Across 82 payments — averaging $25.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$460
- Teva Pharmaceuticals USA, Inc.$431
- Neurocrine Biosciences, Inc.$287
- AbbVie$286
- Otsuka America Pharmaceutical, Inc.$200
- Sunovion Pharmaceuticals Inc.$166
- plus $231 from 6 others
What the payments were for
- Food & beverage$2,01498%
- Education$472%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 20 | $460 |
| Teva Pharmaceuticals USA, Inc. | 15 | $431 |
| Neurocrine Biosciences, Inc. | 4 | $287 |
| AbbVie | 11 | $286 |
| Otsuka America Pharmaceutical, Inc. | 5 | $200 |
| Sunovion Pharmaceuticals Inc. | 13 | $166 |
| Alkermes, Inc. | 5 | $80 |
| Johnson & Johnson | 3 | $62 |
| Merck | 3 | $44 |
| Axsome Therapeutics, Inc. | 1 | $17 |
| Vanda Pharmaceuticals Inc. | 1 | $15 |
| Supernus Pharmaceuticals, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,061 in reported general payments places this provider in the 75th percentile of 2,724 psychiatric/mental health providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 25 | $197,146 |
| VraylarCariprazine Hcl | 46 | $67,047 |
| Invega SustennaPaliperidone Palmitate | 14 | $52,006 |
| Abilify MaintenaAripiprazole | 15 | $41,785 |
| RexultiBrexpiprazole | 18 | $30,930 |
| CaplytaLumateperone Tosylate | 14 | $23,267 |
| Lurasidone Hcl | 40 | $22,815 |
| NuedextaDextromethorphan Hbr/Quinidine | 13 | $19,895 |
| LybalviOlanzapine/Samidorphan Malate | 11 | $18,168 |
| TrintellixVortioxetine Hydrobromide | 26 | $16,025 |
| BelsomraSuvorexant | 29 | $12,922 |
| DayvigoLemborexant | 11 | $3,443 |
| Vilazodone Hcl | 32 | $3,184 |
| Quetiapine Fumarate | 166 | $2,433 |
| Aripiprazole | 109 | $2,418 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $287 | $197,14625 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti | $200 | $72,71633 claims |
| AbbVieVraylar | $286 | $67,04746 claims |
| Johnson & JohnsonInvega Sustenna | $62 | $52,00614 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $460 | $23,26714 claims |
| Alkermes, Inc.Lybalvi | $80 | $18,16811 claims |
| MerckBelsomra | $44 | $12,92229 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,724 psychiatric/mental health providers in Texas.
Other psychiatric/mental health in San Antonio
- Monique GonzalezSan Antonio$126K
- Geoffrey GonzalesSan Antonio$57K
- Sara Koenig LangstonSan Antonio$27K
- Peter TorciviaSan Antonio$13K
- Tracy HicksLongview$684K
- Natalie TellezHouston$602K
- Karah BrashierRichardson$567K
- Grant DavisRichardson$360K
- Victor IlogEl Paso$167K
- Lisa ShamblinGrapevine$163K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.